These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24376706)

  • 1. Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro.
    Cihalova D; Hofman J; Ceckova M; Staud F
    PLoS One; 2013; 8(12):e83467. PubMed ID: 24376706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1).
    Hofman J; Kučera R; Cihalova D; Klimes J; Ceckova M; Staud F
    PLoS One; 2013; 8(10):e75520. PubMed ID: 24116053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone.
    Hofman J; Ahmadimoghaddam D; Hahnova L; Pavek P; Ceckova M; Staud F
    Pharmacol Res; 2012 Mar; 65(3):312-9. PubMed ID: 22173067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.
    Cihalova D; Staud F; Ceckova M
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):105-16. PubMed ID: 25986678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
    Cihalova D; Ceckova M; Kucera R; Klimes J; Staud F
    Biochem Pharmacol; 2015 Dec; 98(3):465-72. PubMed ID: 26300056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro.
    An R; Hagiya Y; Tamura A; Li S; Saito H; Tokushima D; Ishikawa T
    Pharm Res; 2009 Feb; 26(2):449-58. PubMed ID: 18841444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs).
    Hofman J; Kučera R; Neumanova Z; Klimes J; Ceckova M; Staud F
    Xenobiotica; 2016; 46(5):416-23. PubMed ID: 26364927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of autophagy by 3-MA potentiates purvalanol-induced apoptosis in Bax deficient HCT 116 colon cancer cells.
    Coker-Gurkan A; Arisan ED; Obakan P; Guvenir E; Unsal NP
    Exp Cell Res; 2014 Oct; 328(1):87-98. PubMed ID: 25088259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
    Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
    Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
    Iseki H; Ko TC; Xue XY; Seapan A; Hellmich MR; Townsend CM
    Surgery; 1997 Aug; 122(2):187-94; discussion 194-5. PubMed ID: 9288122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.
    Holcakova J; Muller P; Tomasec P; Hrstka R; Nekulova M; Krystof V; Strnad M; Wilkinson GW; Vojtesek B
    PLoS One; 2014; 9(2):e89228. PubMed ID: 24586613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance.
    Löschmann N; Michaelis M; Rothweiler F; Voges Y; Balónová B; Blight BA; Cinatl J
    Oncotarget; 2016 Sep; 7(36):58051-58064. PubMed ID: 27517323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
    Sorf A; Hofman J; Kučera R; Staud F; Ceckova M
    Biochem Pharmacol; 2018 Aug; 154():10-17. PubMed ID: 29673999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells.
    Wang J; Yang DH; Yang Y; Wang JQ; Cai CY; Lei ZN; Teng QX; Wu ZX; Zhao L; Chen ZS
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32092870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.
    Paprskárová M; Krystof V; Jorda R; Dzubák P; Hajdúch M; Wesierska-Gadek J; Strnad M
    J Cell Biochem; 2009 Jun; 107(3):428-37. PubMed ID: 19308936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity.
    Iseki H; Ko TC; Xue XY; Seapan A; Townsend CM
    J Gastrointest Surg; 1998; 2(1):36-43. PubMed ID: 9841966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of polyamine oxidase prevented cyclin-dependent kinase inhibitor-induced apoptosis in HCT 116 colon carcinoma cells.
    Gürkan AC; Arisan ED; Obakan P; Palavan-Ünsal N
    Apoptosis; 2013 Dec; 18(12):1536-47. PubMed ID: 23892915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
    Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
    Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study on ABCB1-dependent efflux of anthracyclines and their metabolites: consequences for cancer resistance.
    Piska K; Koczurkiewicz-Adamczyk P; Jamrozik M; Bucki A; Kołaczkowski M; Pękala E
    Xenobiotica; 2023 Dec; 53(6-7):507-514. PubMed ID: 37753851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.